3rd Quarter - Report

MARSHALL & POPP, LLC for AMGEN USA INC.

Period 3rd Quarter 2019 Filed Oct 16, 2019 Signed by Beth Anne Cole

Official filing
Firm
MARSHALL & POPP, LLC
Client
AMGEN USA INC.
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues.

LobbyistCovered position, as disclosed
HAZEN CLAY MARSHALL Policy Director, Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant, Senator Don Nickles
MONICA POPP Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

Contacted: Natl Economic Council (NEC); Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (116th), S. 2543 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.